- Moderna Inc (NASDAQ:MRNA) and Generation Bio Co (NASDAQ:GBIO) have collaborated to combine the application of each company’s platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.
- “Non-viral DNA therapeutics may offer durable, redosable, titratable genetic medicines to patients suffering from rare and prevalent diseases on a global scale,” said Phillip Samayoa, Chief Strategy Officer of Generation Bio.
- Moderna may advance two immune cell programs using a jointly developed ctLNP to deliver ceDNA.
- In addition, Moderna may advance two liver programs, each of which may use a liver-targeted ctLNP developed by Generation Bio to deliver ceDNA.
- Moderna retains an option to license a third program for either immune cells or the liver.
- Generation Bio will receive a $40 million upfront cash payment and a $36 million equity investment.
- Moderna will fund all collaboration work, including a research pre-payment.
- The agreement additionally gives Moderna the right to purchase additional Generation Bio shares.
- Generation Bio is eligible for certain exclusivity fees, potential development and regulatory milestones, and royalties on products Moderna advances using ctLNP technology developed under the collaboration.
- Price Action: GBIO shares are up 13.4% at $4.40 during the premarket session on the last check Thursday.
What’s Going On With AMC Entertainment Stock?
AMC Entertainment Holdings Inc (NYSE: AMC) shares are moving lower Tuesday, adding to significant losses over the last month.
